Table 2.
Main efficacy and discontinuation outcomes
| Outcome | Duration (weeks) | No of included studies | No of subjects in quetiapine group | No of subjects in placebo group | Mean difference (95% CI) | Risk ratio (95% CI) | Heterogeneity | Quality |
|---|---|---|---|---|---|---|---|---|
| Mean-changed scores of CDRS-R | 8 | 2 | 109 | 115 | −1.829 (−5.98, 2.34) |
I
2=0%, χ2=0.30 (P=0.58) |
Moderate to high | |
| Mean-changed scores of CGI-BP-S | 8 | 2 | 109 | 115 | −0.29 (−0.67, 0.09) |
I
2=0%, χ2=0.02 (P=0.87) |
Moderate to high | |
| Clinical response | 8 | 3 | 125 | 125 | 1.10 (0.89, 1.35) |
I
2=0%, χ2=1.50 (P=0.47) |
Moderate to high | |
| Clinical remission | 8 | 3 | 125 | 125 | 1.23 (0.90, 1.68) |
I
2=0%, χ2=1.06 (P=0.19) |
Moderate to high | |
| Overall discontinuation | 8 | 2 | 110 | 115 | – | 0.73 (0.36, 1.49) |
I
2=47%, χ2=1.90 (P=0.17) |
Moderate to high |
| Discontinuation due to adverse events | 8 | 2 | 110 | 115 | – | 0.33 (0.11, 1.01) |
I
2=0%, χ2=0.63 (P=0.43) |
Moderate to high |
Abbreviations: CDRS-R, Children’s Depression Rating Scale–Revised; CGI-BP-S, Clinical Global Impression–Bipolar Version Severity; CI, confidence interval.